Description of Business and Summary of Significant Accounting Policies (Details)
$ / shares in Units, $ in Thousands |
|
|
|
|
3 Months Ended |
6 Months Ended |
12 Months Ended |
|
Jul. 13, 2015
USD ($)
|
Jan. 30, 2015
shares
|
Jul. 12, 2012
USD ($)
|
Nov. 22, 2011
USD ($)
|
Sep. 30, 2015
USD ($)
Customer
$ / shares
shares
|
Sep. 30, 2014
USD ($)
Customer
|
Sep. 30, 2015
USD ($)
Customer
$ / shares
shares
|
Sep. 30, 2014
USD ($)
Customer
|
Mar. 31, 2015
USD ($)
Customer
$ / shares
shares
|
| Description of Business and Summary of Significant Accounting Policies [Abstract] |
|
|
|
|
|
|
|
|
|
|
| Net loss | $ |
|
|
|
|
$ (956)
|
$ (1,016)
|
$ (2,301)
|
$ (2,264)
|
|
|
| Net cash used in operating activities | $ |
|
|
|
|
|
|
$ (2,335)
|
$ (1,649)
|
|
|
| Minimum bid price (in dollars per share) |
|
|
|
|
$ 1.00
|
|
$ 1.00
|
|
|
|
| Number of calendar days |
|
|
|
|
|
|
|
180 days
|
|
|
| Number of consecutive business days |
|
|
|
|
|
|
|
10 days
|
|
|
| Unrealized gain on this investment | $ |
|
|
|
|
$ 41
|
|
$ 460
|
$ 0
|
|
|
| Other comprehensive income (loss) | $ |
|
|
|
|
$ 41
|
0
|
$ 460
|
0
|
|
|
| Short-term Debt [Line Items] |
|
|
|
|
|
|
|
|
|
|
| Percentage of common stock outstanding |
|
8.90%
|
|
|
|
|
|
|
|
|
| Common stock shares outstanding (in shares) | shares |
|
2,289,682
|
|
|
10,487,373
|
|
10,487,373
|
|
10,469,120
|
|
| Convertible promissory note balance | $ |
|
|
|
|
|
|
|
|
$ 399
|
|
| Original amount | $ |
|
|
|
|
|
|
|
|
300
|
|
| Accrued interest on note receivable | $ |
|
|
|
|
|
|
|
|
99
|
|
| Business Acquisition [Line Items] |
|
|
|
|
|
|
|
|
|
|
| Business acquisition effective date |
|
|
|
|
|
|
Jul. 12, 2012
|
|
|
|
| Promissory note assumed | $ |
|
|
$ 500
|
|
|
|
|
|
|
|
| Principal and accrued interest payments of promissory note in 2015 | $ |
$ 208
|
|
|
|
|
|
|
|
|
|
| Principal and accrued interest payments of promissory note in 2016 | $ |
|
|
|
|
|
|
$ 167
|
|
|
|
| Principal and accrued interest payments of promissory note in 2017 | $ |
|
|
|
|
|
|
$ 166
|
|
|
|
| Note receivable used as consideration for CollabRx acquisition | $ |
|
|
|
$ 300
|
|
|
|
|
|
|
| Interest rate on promissory note |
|
|
|
10.00%
|
|
|
|
|
|
|
| Promissory note maturity date |
|
|
|
|
|
|
Nov. 15, 2014
|
|
|
|
| Accounts Receivable - Allowance for Sales Returns and Doubtful Accounts [Abstract] |
|
|
|
|
|
|
|
|
|
|
| Reserves for potential credit losses | $ |
|
|
|
|
$ 0
|
|
$ 0
|
|
0
|
|
| Fair Value measurements [Abstract] |
|
|
|
|
|
|
|
|
|
|
| Investments | $ |
|
|
|
|
859
|
|
859
|
|
$ 399
|
[1] |
| Finite-Lived Intangible Assets [Line Items] |
|
|
|
|
|
|
|
|
|
|
| Impairment of intangible assets | $ |
|
|
|
|
0
|
0
|
0
|
0
|
|
|
| Impairment of goodwill | $ |
|
|
|
|
0
|
0
|
0
|
0
|
|
|
| Amortization of intangible assets | $ |
|
|
|
|
43
|
52
|
$ 103
|
104
|
|
|
| Stock-Based Compensation [Abstract] |
|
|
|
|
|
|
|
|
|
|
| Vesting period of equity awards |
|
|
|
|
|
|
4 years
|
|
|
|
| Stock options expiry period |
|
|
|
|
|
|
10 years
|
|
|
|
| Purchase price of shares to fair market value |
|
|
|
|
|
|
85.00%
|
|
|
|
| Total stock-based compensation expense related to stock options and restricted stock units | $ |
|
|
|
|
$ 32
|
$ 160
|
$ 68
|
$ 253
|
|
|
| Stock option and warrant activity [Roll Forward] |
|
|
|
|
|
|
|
|
|
|
| Granted (in shares) | shares |
|
|
|
|
|
|
0
|
|
|
|
| Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items] |
|
|
|
|
|
|
|
|
|
|
| Number Outstanding (in shares) | shares |
|
|
|
|
587,059
|
|
587,059
|
|
|
|
| Weighted Average Remaining Contractual Term |
|
|
|
|
|
|
7 years 4 months 17 days
|
|
|
|
| Weighted Average Exercise Price (in dollars per share) |
|
|
|
|
$ 4.24
|
|
$ 4.24
|
|
|
|
| Number Exercisable (in shares) | shares |
|
|
|
|
304,380
|
|
304,380
|
|
|
|
| Weighted Average Exercise Price (in dollars per share) |
|
|
|
|
$ 6.74
|
|
$ 6.74
|
|
|
|
| Board of Directors [Member] |
|
|
|
|
|
|
|
|
|
|
| Stock option and warrant activity [Roll Forward] |
|
|
|
|
|
|
|
|
|
|
| Granted (in shares) | shares |
|
|
|
|
|
|
0
|
|
|
|
| Minimum [Member] |
|
|
|
|
|
|
|
|
|
|
| Finite-Lived Intangible Assets [Line Items] |
|
|
|
|
|
|
|
|
|
|
| Useful life |
|
|
|
|
|
|
3 years
|
|
|
|
| Maximum [Member] |
|
|
|
|
|
|
|
|
|
|
| Finite-Lived Intangible Assets [Line Items] |
|
|
|
|
|
|
|
|
|
|
| Useful life |
|
|
|
|
|
|
10 years
|
|
|
|
| Nano Vibronix [Member] |
|
|
|
|
|
|
|
|
|
|
| Short-term Debt [Line Items] |
|
|
|
|
|
|
|
|
|
|
| Convertible preferred stock, shares issued upon conversion (in shares) | shares |
|
204,507
|
|
|
|
|
|
|
|
|
| Software [Member] |
|
|
|
|
|
|
|
|
|
|
| Finite-Lived Intangible Assets [Line Items] |
|
|
|
|
|
|
|
|
|
|
| Useful life |
|
|
|
|
|
|
10 years
|
|
|
|
| Software [Member] | Minimum [Member] |
|
|
|
|
|
|
|
|
|
|
| Finite-Lived Intangible Assets [Line Items] |
|
|
|
|
|
|
|
|
|
|
| Useful life |
|
|
|
|
|
|
3 years
|
|
|
|
| Software [Member] | Maximum [Member] |
|
|
|
|
|
|
|
|
|
|
| Finite-Lived Intangible Assets [Line Items] |
|
|
|
|
|
|
|
|
|
|
| Useful life |
|
|
|
|
|
|
10 years
|
|
|
|
| Trade Names [Member] | Minimum [Member] |
|
|
|
|
|
|
|
|
|
|
| Finite-Lived Intangible Assets [Line Items] |
|
|
|
|
|
|
|
|
|
|
| Useful life |
|
|
|
|
|
|
3 years
|
|
|
|
| Trade Names [Member] | Maximum [Member] |
|
|
|
|
|
|
|
|
|
|
| Finite-Lived Intangible Assets [Line Items] |
|
|
|
|
|
|
|
|
|
|
| Useful life |
|
|
|
|
|
|
10 years
|
|
|
|
| Customer Relationships [Member] |
|
|
|
|
|
|
|
|
|
|
| Finite-Lived Intangible Assets [Line Items] |
|
|
|
|
|
|
|
|
|
|
| Useful life |
|
|
|
|
|
|
5 years
|
|
|
|
| Customer Relationships [Member] | Minimum [Member] |
|
|
|
|
|
|
|
|
|
|
| Finite-Lived Intangible Assets [Line Items] |
|
|
|
|
|
|
|
|
|
|
| Useful life |
|
|
|
|
|
|
3 years
|
|
|
|
| Customer Relationships [Member] | Maximum [Member] |
|
|
|
|
|
|
|
|
|
|
| Finite-Lived Intangible Assets [Line Items] |
|
|
|
|
|
|
|
|
|
|
| Useful life |
|
|
|
|
|
|
10 years
|
|
|
|
| Noncompete Agreements [Member] | Minimum [Member] |
|
|
|
|
|
|
|
|
|
|
| Finite-Lived Intangible Assets [Line Items] |
|
|
|
|
|
|
|
|
|
|
| Useful life |
|
|
|
|
|
|
3 years
|
|
|
|
| Noncompete Agreements [Member] | Maximum [Member] |
|
|
|
|
|
|
|
|
|
|
| Finite-Lived Intangible Assets [Line Items] |
|
|
|
|
|
|
|
|
|
|
| Useful life |
|
|
|
|
|
|
10 years
|
|
|
|
| Patents [Member] | Minimum [Member] |
|
|
|
|
|
|
|
|
|
|
| Finite-Lived Intangible Assets [Line Items] |
|
|
|
|
|
|
|
|
|
|
| Useful life |
|
|
|
|
|
|
3 years
|
|
|
|
| Patents [Member] | Maximum [Member] |
|
|
|
|
|
|
|
|
|
|
| Finite-Lived Intangible Assets [Line Items] |
|
|
|
|
|
|
|
|
|
|
| Useful life |
|
|
|
|
|
|
10 years
|
|
|
|
| Trademarks [Member] | Minimum [Member] |
|
|
|
|
|
|
|
|
|
|
| Finite-Lived Intangible Assets [Line Items] |
|
|
|
|
|
|
|
|
|
|
| Useful life |
|
|
|
|
|
|
3 years
|
|
|
|
| Trademarks [Member] | Maximum [Member] |
|
|
|
|
|
|
|
|
|
|
| Finite-Lived Intangible Assets [Line Items] |
|
|
|
|
|
|
|
|
|
|
| Useful life |
|
|
|
|
|
|
10 years
|
|
|
|
| Range $0.75 to $1.50 [Member] |
|
|
|
|
|
|
|
|
|
|
| Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items] |
|
|
|
|
|
|
|
|
|
|
| Range of Exercise Prices, Lower Range Limit (in dollars per share) |
|
|
|
|
|
|
$ 0.75
|
|
|
|
| Range of Exercise Prices, Upper Range Limit (in dollars per share) |
|
|
|
|
|
|
$ 1.50
|
|
|
|
| Number Outstanding (in shares) | shares |
|
|
|
|
206,679
|
|
206,679
|
|
|
|
| Weighted Average Remaining Contractual Term |
|
|
|
|
|
|
9 years 2 months 1 day
|
|
|
|
| Weighted Average Exercise Price (in dollars per share) |
|
|
|
|
$ 0.8
|
|
$ 0.8
|
|
|
|
| Number Exercisable (in shares) | shares |
|
|
|
|
20,000
|
|
20,000
|
|
|
|
| Weighted Average Exercise Price (in dollars per share) |
|
|
|
|
$ 1.28
|
|
$ 1.28
|
|
|
|
| Range $1.99 to $3.22 [Member] |
|
|
|
|
|
|
|
|
|
|
| Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items] |
|
|
|
|
|
|
|
|
|
|
| Range of Exercise Prices, Lower Range Limit (in dollars per share) |
|
|
|
|
|
|
1.99
|
|
|
|
| Range of Exercise Prices, Upper Range Limit (in dollars per share) |
|
|
|
|
|
|
$ 3.22
|
|
|
|
| Number Outstanding (in shares) | shares |
|
|
|
|
159,067
|
|
159,067
|
|
|
|
| Weighted Average Remaining Contractual Term |
|
|
|
|
|
|
8 years 7 months 2 days
|
|
|
|
| Weighted Average Exercise Price (in dollars per share) |
|
|
|
|
$ 2.54
|
|
$ 2.54
|
|
|
|
| Number Exercisable (in shares) | shares |
|
|
|
|
87,317
|
|
87,317
|
|
|
|
| Weighted Average Exercise Price (in dollars per share) |
|
|
|
|
$ 2.36
|
|
$ 2.36
|
|
|
|
| Range $3.35 to $6.00 [Member] |
|
|
|
|
|
|
|
|
|
|
| Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items] |
|
|
|
|
|
|
|
|
|
|
| Range of Exercise Prices, Lower Range Limit (in dollars per share) |
|
|
|
|
|
|
3.35
|
|
|
|
| Range of Exercise Prices, Upper Range Limit (in dollars per share) |
|
|
|
|
|
|
$ 6.00
|
|
|
|
| Number Outstanding (in shares) | shares |
|
|
|
|
138,997
|
|
138,997
|
|
|
|
| Weighted Average Remaining Contractual Term |
|
|
|
|
|
|
6 years 2 months 19 days
|
|
|
|
| Weighted Average Exercise Price (in dollars per share) |
|
|
|
|
$ 3.91
|
|
$ 3.91
|
|
|
|
| Number Exercisable (in shares) | shares |
|
|
|
|
114,747
|
|
114,747
|
|
|
|
| Weighted Average Exercise Price (in dollars per share) |
|
|
|
|
$ 3.9
|
|
$ 3.9
|
|
|
|
| Range $11.70 to $17.80 [Member] |
|
|
|
|
|
|
|
|
|
|
| Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items] |
|
|
|
|
|
|
|
|
|
|
| Range of Exercise Prices, Lower Range Limit (in dollars per share) |
|
|
|
|
|
|
11.70
|
|
|
|
| Range of Exercise Prices, Upper Range Limit (in dollars per share) |
|
|
|
|
|
|
$ 17.80
|
|
|
|
| Number Outstanding (in shares) | shares |
|
|
|
|
46,191
|
|
46,191
|
|
|
|
| Weighted Average Remaining Contractual Term |
|
|
|
|
|
|
3 years 1 month 2 days
|
|
|
|
| Weighted Average Exercise Price (in dollars per share) |
|
|
|
|
$ 12.03
|
|
$ 12.03
|
|
|
|
| Number Exercisable (in shares) | shares |
|
|
|
|
46,191
|
|
46,191
|
|
|
|
| Weighted Average Exercise Price (in dollars per share) |
|
|
|
|
$ 12.03
|
|
$ 12.03
|
|
|
|
| Range $21.00 to $34.20 [Member] |
|
|
|
|
|
|
|
|
|
|
| Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items] |
|
|
|
|
|
|
|
|
|
|
| Range of Exercise Prices, Lower Range Limit (in dollars per share) |
|
|
|
|
|
|
21.00
|
|
|
|
| Range of Exercise Prices, Upper Range Limit (in dollars per share) |
|
|
|
|
|
|
$ 34.20
|
|
|
|
| Number Outstanding (in shares) | shares |
|
|
|
|
36,125
|
|
36,125
|
|
|
|
| Weighted Average Remaining Contractual Term |
|
|
|
|
|
|
1 year 9 months 14 days
|
|
|
|
| Weighted Average Exercise Price (in dollars per share) |
|
|
|
|
$ 22.64
|
|
$ 22.64
|
|
|
|
| Number Exercisable (in shares) | shares |
|
|
|
|
36,125
|
|
36,125
|
|
|
|
| Weighted Average Exercise Price (in dollars per share) |
|
|
|
|
$ 22.63
|
|
$ 22.63
|
|
|
|
| Revenue [Member] |
|
|
|
|
|
|
|
|
|
|
| Concentration Risk [Line Items] |
|
|
|
|
|
|
|
|
|
|
| Number of major customers | Customer |
|
|
|
|
4
|
3
|
4
|
4
|
|
|
| Revenue [Member] | Customer 1 [Member] |
|
|
|
|
|
|
|
|
|
|
| Concentration Risk [Line Items] |
|
|
|
|
|
|
|
|
|
|
| Concentration risk |
|
|
|
|
31.70%
|
28.40%
|
25.40%
|
20.90%
|
|
|
| Revenue [Member] | Customer 2 [Member] |
|
|
|
|
|
|
|
|
|
|
| Concentration Risk [Line Items] |
|
|
|
|
|
|
|
|
|
|
| Concentration risk |
|
|
|
|
20.50%
|
28.40%
|
21.70%
|
20.90%
|
|
|
| Revenue [Member] | Customer 3 [Member] |
|
|
|
|
|
|
|
|
|
|
| Concentration Risk [Line Items] |
|
|
|
|
|
|
|
|
|
|
| Concentration risk |
|
|
|
|
15.50%
|
14.20%
|
13.00%
|
17.40%
|
|
|
| Revenue [Member] | Customer 4 [Member] |
|
|
|
|
|
|
|
|
|
|
| Concentration Risk [Line Items] |
|
|
|
|
|
|
|
|
|
|
| Concentration risk |
|
|
|
|
12.30%
|
|
12.50%
|
10.40%
|
|
|
| Accounts Receivable [Member] |
|
|
|
|
|
|
|
|
|
|
| Concentration Risk [Line Items] |
|
|
|
|
|
|
|
|
|
|
| Number of major customers | Customer |
|
|
|
|
|
|
1
|
2
|
3
|
|
| Concentration risk |
|
|
|
|
|
|
98.00%
|
92.10%
|
95.00%
|
|
| Stock Options [Member] |
|
|
|
|
|
|
|
|
|
|
| Valuation assumptions to estimate the fair value of options and ESPP [Abstract] |
|
|
|
|
|
|
|
|
|
|
| Expected life |
|
|
|
|
|
6 years
|
|
6 years
|
|
|
| Volatility, minimum |
|
|
|
|
|
143.10%
|
|
143.10%
|
|
|
| Volatility, maximum |
|
|
|
|
|
148.50%
|
|
151.70%
|
|
|
| Risk-free interest rate, minimum |
|
|
|
|
|
1.63%
|
|
1.63%
|
|
|
| Risk free interest rate, maximum |
|
|
|
|
|
1.75%
|
|
1.75%
|
|
|
| Dividend yield |
|
|
|
|
|
0.00%
|
|
0.00%
|
|
|
| Forfeiture rate |
|
|
|
|
|
10.00%
|
|
10.00%
|
|
|
| Stock option and warrant activity [Roll Forward] |
|
|
|
|
|
|
|
|
|
|
| Beginning outstanding (in shares) | shares |
|
|
|
|
|
|
665,058
|
|
|
|
| Granted (in shares) | shares |
|
|
|
|
|
|
0
|
|
|
|
| Forfeited (in shares) | shares |
|
|
|
|
|
|
(49,938)
|
|
|
|
| Expired (in shares) | shares |
|
|
|
|
|
|
(28,061)
|
|
|
|
| Ending outstanding (in shares) | shares |
|
|
|
|
587,059
|
|
587,059
|
|
665,058
|
|
| Ending vested and expected to vest (in shares) | shares |
|
|
|
|
586,935
|
|
586,935
|
|
|
|
| Ending exercisable (in shares) | shares |
|
|
|
|
304,380
|
|
304,380
|
|
|
|
| Weighted Average Exercise Price [Abstract] |
|
|
|
|
|
|
|
|
|
|
| Beginning outstanding (in dollars per share) |
|
|
|
|
|
|
$ 4.79
|
|
|
|
| Granted (in dollars per share) |
|
|
|
|
|
|
0
|
|
|
|
| Forfeited (in dollars per share) |
|
|
|
|
|
|
2.54
|
|
|
|
| Expired (in dollars per share) |
|
|
|
|
|
|
20.28
|
|
|
|
| Ending outstanding (in dollars per share) |
|
|
|
|
$ 4.24
|
|
4.24
|
|
$ 4.79
|
|
| Ending vested and expected to vest (in dollars per share) |
|
|
|
|
4.24
|
|
4.24
|
|
|
|
| Ending exercisable (in dollars per share) |
|
|
|
|
$ 6.74
|
|
$ 6.74
|
|
|
|
| Weighted Average Remaining Contractual Term [Abstract] |
|
|
|
|
|
|
|
|
|
|
| Outstanding |
|
|
|
|
|
|
7 years 4 months 17 days
|
|
7 years 9 months 18 days
|
|
| Ending vested and expected to vest |
|
|
|
|
|
|
7 years 4 months 17 days
|
|
|
|
| Ending exercisable |
|
|
|
|
|
|
6 years 4 days
|
|
|
|
| Aggregate Intrinsic Value [Abstract] |
|
|
|
|
|
|
|
|
|
|
| Beginning outstanding | $ |
|
|
|
|
|
|
$ 67,951
|
|
|
|
| Ending outstanding | $ |
|
|
|
|
$ 0
|
|
0
|
|
$ 67,951
|
|
| Ending vested and expected to vest | $ |
|
|
|
|
0
|
|
0
|
|
|
|
| Ending exercisable | $ |
|
|
|
|
0
|
|
0
|
|
|
|
| Total unrecognized compensation cost related to outstanding options and warrants | $ |
|
|
|
|
164
|
|
$ 164
|
|
|
|
| Period of recognition of total unrecognized compensation cost related to options outstanding |
|
|
|
|
|
|
1 year 2 months 19 days
|
|
|
|
| Restricted Stock Units (RSUs) [Member] |
|
|
|
|
|
|
|
|
|
|
| Restricted Stock Units [Abstract] |
|
|
|
|
|
|
|
|
|
|
| Total unrecognized compensation cost related to outstanding RSUs | $ |
|
|
|
|
$ 0
|
|
$ 0
|
|
|
|
| Granted (in shares) | shares |
|
|
|
|
|
|
0
|
|
|
|
| Outstanding (in shares) | shares |
|
|
|
|
23,921
|
|
23,921
|
|
|
|
|
|